Nuvectis licenses two clinical-stage compounds from Haisco

Nuvectis Pharma, Inc. (NASDAQ: NVCT) announced a license agreement with Haisco Pharmaceutical Group (SHE: 002653) granting Nuvectis exclusive ex-China rights to two clinical-stage drug candidates, according to a company press release.

The agreement covers NXP100, an oral once-daily Complement Factor B inhibitor, and NXP200, an oral brain-penetrant paradox-breaker BRAF inhibitor. Haisco retains rights to NXP100 in India and certain Southeast Asia territories.

Under the terms, Haisco will receive upfront and near-term payments totaling up to $40 million, with eligibility for up to $1.421 billion in development, regulatory, and commercial milestone payments, plus tiered royalties on future net sales. The agreement is subject to financing conditions that Nuvectis must meet to fund development of the licensed compounds.

NXP100 is in late-stage development in China, where two Marketing Authorization Applications for Paroxysmal Nocturnal Hemoglobinuria are under review by China's National Medical Products Administration. In a completed Phase 3 study, 59.5% of treatment-naive PNH patients receiving NXP100 achieved hemoglobin levels of 12 g/dL or higher without transfusion, compared with 8.3% for eculizumab. A Phase 3 trial in IgA Nephropathy is ongoing following positive Phase 2 results, and a Phase 2 trial in Lupus Nephritis is also underway in China.

NXP200 has shown single-agent responses in several tumor types in a completed dose escalation study, including a greater than 40% response rate in adult glioma. A Phase 1b study is ongoing in China. Composition of matter patents for NXP100 and NXP200 expire in 2043 and 2042, respectively.

Nuvectis Chairman and CEO Ron Bentsur stated that the in-licensing "represents an expansion of Nuvectis' pipeline and strategy." Haisco CEO Dr. Pangke Yan said the deal "further strengthens Haisco's global research and development presence."

You May Also Be Interested In

• Faraday Future signs robotics distributor deal, plans partner event
• Gossamer Bio raises up to $250M in private placement for PAH drug
• Andersen closes secondary offering of 4.9M shares at $44 each